Previous 10 | Next 10 |
home / stock / bctxw / bctxw news
PFS of 4.2 months in Phase 2 ADC resistant patients receiving Bria-IMT™ pivotal Phase 3 formulation is twice that of controls in similar studies PFS results reinforced by larger number of prior treatments in Bria-IMT™ population than in comparable studies Bri...
Agreement with a leading cancer treatment group to advance the clinical development of Bria-OTS+ (breast cancer) and Bria-PROS+ (prostate cancer), BriaCell’s novel off-the-shelf personalized cancer vaccines, marks a major milestone for BriaCell PHILADELPHIA and VANCOUVER, British...
PHILADELPHIA and VANCOUVER, British Columbia, March 06, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer c...
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies t...
2024-02-07 08:30:54 ET More on Briacell Therapeutics, BriaCell Therapeutics Corp. WT EX 022425, etc. Seeking Alpha’s Quant Rating on Briacell Therapeutics Historical earnings data for Briacell Therapeutics Financial information for Briacell Therapeutics ...
Disease control rate of 61% observed in evaluable Phase 2 patients treated with the same formulation in BriaCell’s pivotal Phase 3 study Disease control rate of 50% in evaluable patients treated with the Phase 3 formulation who failed prior antibody-drug conjugate (ADC) therapy...
Bria-Pros+ is based on BriaCell’s next generation personalized immunotherapy platform Bria-Pros+ is capable of activating multiple types of immune cells, including helper T cells, cytotoxic (killer) T cells and natural killer cells Initiation of GMP manufacturing ...
Significant reduction of metastatic breast cancer tumor behind-the-eye after only 3 cycles Powerful anti-tumor response associated with reduction in proptosis (eye-bulging) and reduced ocular pain Heavily pre-treated patient had failed 7 prior regimens including ant...
71% intracranial objective response rate (iORR) in BriaCell patients with Central Nervous System (CNS) metastases support clinical efficacy of Bria-IMT™, alone and in combination with an immune checkpoint inhibitor (CPI) Tumor reductions observed in heavily pretreated patient...
In the subset of Antibody-Drug Conjugate (ADC) refractory patients, Overall Survival (OS) data of BriaCell’s combination regimen exceeded that of similar studies* Progression Free Survival (PFS) was similar or better than last regimen in 40% of the patients highlighting clinica...
News, Short Squeeze, Breakout and More Instantly...
BriaCell Therapeutics Corp. Warrant Company Name:
BCTXW Stock Symbol:
NASDAQ Market:
BriaCell Therapeutics Corp. Warrant Website:
Progression free survival (PFS) extended to 9.1 months in ADC resistant patient - quadruple the PFS of patients in similar studies 1, 2, 3 Significant reduction of “Eye-Bulging” metastatic breast cancer tumor was previously rep...
BriaCell doubles Progression-Free-Survival (PFS) and Clinical Benefit Rate vs historical results in the literature Bria-IMT™ PFS compares favorably to PFS of most recent treatment in 48% of Antibody-Drug Conjugate (ADC) resistant patients Therapy well-tolerate...
PHILADELPHIA and VANCOUVER, British Columbia, May 30, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer car...